Praxis Precision Medicines IPO

10/15/2020

IPO

$190,000,000

Management says it will use the net proceeds from the IPO as follows:approximately $70 to $80 million to advance PRAX-114 into and through the completion of our Phase 2/3 trial in MDD, which is intended to satisfy one of two registrational trials required by the FDA to support clinical efficacy, and to complete Part B (PMD) and Part C (longer-term dosing in MDD) of our ongoing Phase 2a clinical trial for PRAX-114;approximately $30 to $40 million to complete our ongoing Phase 2a clinical trial and a Phase 2/3 randomized, controlled clinical trial for PRAX-944 in ET;approximately $20 to $30 million to complete our ongoing Phase 1 healthy volunteer trial and the first patient trial for PRAX-562; andthe remainder for advancement of other programs in our pipeline and support of working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

1 Bdwy. 16th Floor
Cambridge, MA 02142
USA

Praxis (Nasdaq: PRAX) is a genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders. At Praxis we get things done. Praxis is the process of using a theory or something that you have learned in a practical way.